[go: up one dir, main page]

DE69710757D1 - Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe - Google Patents

Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe

Info

Publication number
DE69710757D1
DE69710757D1 DE69710757T DE69710757T DE69710757D1 DE 69710757 D1 DE69710757 D1 DE 69710757D1 DE 69710757 T DE69710757 T DE 69710757T DE 69710757 T DE69710757 T DE 69710757T DE 69710757 D1 DE69710757 D1 DE 69710757D1
Authority
DE
Germany
Prior art keywords
hours
mum
form containing
milnaciprane
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69710757T
Other languages
English (en)
Other versions
DE69710757T2 (de
Inventor
Bruno Paillard
Eric Goutay
Jean-Louis Avan
Jo L Bougaret
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of DE69710757D1 publication Critical patent/DE69710757D1/de
Application granted granted Critical
Publication of DE69710757T2 publication Critical patent/DE69710757T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Polishing Bodies And Polishing Tools (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE69710757T 1996-08-28 1997-08-26 Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe Expired - Lifetime DE69710757T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9610528A FR2752732B1 (fr) 1996-08-28 1996-08-28 Forme galenique a liberation prolongee de milnacipran
FR9610528 1996-08-28
PCT/FR1997/001525 WO1998008495A1 (fr) 1996-08-28 1997-08-26 Forme galenique a liberation prolongee de milnacipran

Publications (2)

Publication Number Publication Date
DE69710757D1 true DE69710757D1 (de) 2002-04-04
DE69710757T2 DE69710757T2 (de) 2004-11-04

Family

ID=9495256

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69710757T Expired - Lifetime DE69710757T2 (de) 1996-08-28 1997-08-26 Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe

Country Status (14)

Country Link
US (1) US6699506B1 (de)
EP (1) EP0939626B1 (de)
JP (2) JP4549442B2 (de)
CN (1) CN1108791C (de)
AT (1) ATE213629T1 (de)
AU (1) AU727018B2 (de)
BR (1) BR9711378A (de)
CA (1) CA2264238C (de)
DE (1) DE69710757T2 (de)
DK (1) DK0939626T3 (de)
ES (1) ES2171991T3 (de)
FR (1) FR2752732B1 (de)
PT (1) PT939626E (de)
WO (1) WO1998008495A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19928312A1 (de) * 1999-06-16 2000-12-21 Schering Ag Arzneimittelzubereitung mit verzögerter Wirkstoffabgabe
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
WO2003084517A2 (fr) * 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules d’amoxicilline
US20060024366A1 (en) * 2002-10-25 2006-02-02 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004039361A1 (en) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
MXPA05008033A (es) * 2003-01-28 2006-04-28 Collegium Pharmaceutical Inc Composiciones de milnacipran en forma de multiparticulas para administracion oral.
FR2851163B1 (fr) 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
ES2310715T3 (es) * 2003-02-14 2009-01-16 Pierre Fabre Medicament Uso del enantiomero (1s,2r) del milnacipran para la preparacion de un medicamento.
WO2006132307A1 (ja) 2005-06-10 2006-12-14 Pierre Fabre Medicament S.A. 安定化されたミルナシプラン製剤
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080319083A1 (en) * 2006-01-27 2008-12-25 Asahi Kasei Pharma Corporation Medicine for transnasal administration
EP2144599B1 (de) * 2007-03-02 2010-08-04 Farnam Companies, Inc. Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
CN101301283B (zh) * 2007-05-10 2011-04-06 上海医药工业研究院 一种米那普仑的经鼻脑转运组合物
EP2110129A1 (de) 2008-04-18 2009-10-21 Pierre Fabre Medicament Verwendung von Enanotimer (1S, 2R) Milnacipran-Hydrochlorid zur präventiven Behandlung von Suizidverhalten bei depressiven Patienten
US10668012B2 (en) * 2008-09-04 2020-06-02 Farnam Companies, Inc. Chewable sustained release formulations
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
US20100239681A1 (en) * 2009-03-20 2010-09-23 Biokey, Inc. Controlled Release Particulates Containing Water-Insoluble Drug
FR2943546A1 (fr) * 2009-03-31 2010-10-01 Nouveaux Produits Pharma Sas Excipient pharmaceutique fonctionnalise ameliorant la biodisponibilite de substances actives peu solubles, microgranules l'incorporant.
FR2945449B1 (fr) 2009-05-15 2012-10-05 Pf Medicament Procede d'impregnation par co2 supercritique
MX2012001393A (es) 2009-08-05 2012-08-03 Lupin Ltd Composiciones farmacéuticas de liberación controlada de milnacipran.
CA2779711C (en) * 2009-11-06 2016-11-01 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
CA2790933A1 (en) * 2010-01-14 2011-07-21 Forest Laboratories Holdings Limited Stable dosage forms of levomilnacipran
WO2011107921A2 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Modified release composition of milnacipran
WO2011107922A2 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Extended release composition of milnacipran
US8916194B2 (en) 2010-08-30 2014-12-23 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
FR2978350B1 (fr) 2011-07-28 2013-11-08 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
CN102793683B (zh) * 2012-09-04 2013-04-17 海南康虹医药科技开发有限公司 一种含左旋米那普仑的缓释组合物及其制备方法
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
JP6186139B2 (ja) * 2013-03-08 2017-08-23 杏林製薬株式会社 口腔内速崩壊性錠剤
CN105769823A (zh) * 2014-12-24 2016-07-20 上海星泰医药科技有限公司 一种左旋盐酸米那普仑缓释胶囊及其制备方法
EP3167879A1 (de) * 2015-11-10 2017-05-17 Evonik Technochemie GmbH Aktives abgabesysteme bei magenretention
CN110711185A (zh) * 2018-07-11 2020-01-21 北京万全德众医药生物技术有限公司 左旋米那普仑缓释胶囊
JP7315383B2 (ja) * 2019-06-27 2023-07-26 株式会社Ｓｃｒｅｅｎホールディングス インクジェット用水性組成物及び固体製剤
CN114569566A (zh) * 2020-12-02 2022-06-03 四川科瑞德制药股份有限公司 一种盐酸米那普仑制剂的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2508035A1 (fr) * 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
JPS58180481A (ja) 1982-04-15 1983-10-21 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
FR2581060B1 (fr) * 1985-04-25 1988-07-01 Pf Medicament Procede industriel d'obtention du midalcipran
FR2581059B1 (fr) * 1985-04-25 1988-04-22 Pf Medicament Procede de preparation du chlorhydrate de phenyl-1 diethyl amino carbonyl-1 aminomethyl-2 cyclopropane (z)
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
FR2640972B1 (de) * 1988-12-28 1991-04-19 Pf Medicament
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
FR2677019B1 (fr) 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
AU663780B2 (en) 1992-03-31 1995-10-19 Glaxo Group Limited Substituted phenylcarbamates and phenylureas, their preparation and their use as 5-HT antagonists
JP3839467B2 (ja) * 1992-06-04 2006-11-01 スミスクライン・ビーチャム・コーポレイション 味の良い医薬組成物
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use

Also Published As

Publication number Publication date
CN1232387A (zh) 1999-10-20
EP0939626A1 (de) 1999-09-08
AU4121297A (en) 1998-03-19
FR2752732A1 (fr) 1998-03-06
CA2264238C (fr) 2009-02-24
DK0939626T3 (da) 2002-05-27
JP5431214B2 (ja) 2014-03-05
FR2752732B1 (fr) 1998-11-20
JP2000516946A (ja) 2000-12-19
ES2171991T3 (es) 2002-09-16
BR9711378A (pt) 1999-08-17
PT939626E (pt) 2002-07-31
EP0939626B1 (de) 2002-02-27
CA2264238A1 (fr) 1998-03-05
CN1108791C (zh) 2003-05-21
US6699506B1 (en) 2004-03-02
WO1998008495A1 (fr) 1998-03-05
AU727018B2 (en) 2000-11-30
JP4549442B2 (ja) 2010-09-22
DE69710757T2 (de) 2004-11-04
JP2010163447A (ja) 2010-07-29
ATE213629T1 (de) 2002-03-15

Similar Documents

Publication Publication Date Title
DE69710757D1 (de) Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe
HK95590A (en) Controlled release naproxen and naproxen sodium tablets
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
IL211075A (en) Multi-component preparation with irregular release
GEP20043334B (en) Hydrogel-Driven Drug Dosage Form
MX9701465A (es) Formulacion de acetaminofeno, de liberacion sostenida.
AU5680100A (en) Controlled release and taste masking oral pharmaceutical compositions
DE69816951D1 (de) Zubereitung enthaltend Cefaclor oder Cephalexin mit modifizierter Freisetzungsmatrix
GR1002564B (el) Στερεα απο του στοματος χορηγουμενη φαρμακευτικη μορφη δοσιμετρησεως προγραμματισμενου ρυθμου απελευθερωσεως.
KR920703046A (ko) 경구용 항응고제/혈소판 억제제 저용량 제형
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
DE68909772D1 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
CA2000932A1 (en) Oral pharmaceutical controlled release multiple unit dosage form
ATE253354T1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
CA2417887A1 (en) Particulate composition of eletriptan
ATE367153T1 (de) Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
BR9508202A (pt) Forma medicinal de carbamazepina com liberação de substáncia atíva retardada
DE69634080D1 (de) Mittel zur verhinderung der truebung der vorderen linsenkapsel
CA2356306A1 (en) Sulfated phosphatidylinositols, their preparation and use
EP0761209A3 (de) Ranitidinformulierungen mit gesteuerter Freisetzung
GB9420748D0 (en) 1,5 benzodiazepine derivatives
JO1881B1 (en) Formula II for multi unit disc calibration

Legal Events

Date Code Title Description
8364 No opposition during term of opposition